NASDAQ:ALT
Altimmune, Inc. Stock News
$7.07
+0.520 (+7.94%)
At Close: May 01, 2024
Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B
11:30am, Tuesday, 11'th Apr 2023 GlobeNewswire Inc.
GAITHERSBURG, Md., April 11, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company (the Company), today announced that it has completed enrollment in its
7 Analysts Have This to Say About Altimmune
03:01pm, Friday, 31'st Mar 2023 Benzinga
Analysts have provided the following ratings for Altimmune (NASDAQ:ALT) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
4
1
0
0
Last 3
7 Top Penny Stocks Under $5; Time To Buy Now?
03:28pm, Wednesday, 29'th Mar 2023 PennyStocks
Penny stocks to watch before next week.
The post 7 Top Penny Stocks Under $5; Time To Buy Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
7 Top Penny Stocks Under $5; Time To Buy Now?
11:28am, Wednesday, 29'th Mar 2023
Penny stocks to watch before next week. The post 7 Top Penny Stocks Under $5; Time To Buy Now?
Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%?
09:54am, Wednesday, 29'th Mar 2023 The Motley Fool
Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making.
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
08:05pm, Monday, 27'th Mar 2023 GlobeNewswire Inc.
GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to
4 Top Penny Stocks Under $5; Time To Buy Now?
02:31pm, Monday, 27'th Mar 2023 PennyStocks
Penny stocks to buy for under $5. Are they worth it?
The post 4 Top Penny Stocks Under $5; Time To Buy Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
4 Top Penny Stocks Under $5; Time To Buy Now?
10:31am, Monday, 27'th Mar 2023
Penny stocks to buy for under $5. Are they worth it?
Is Viking Therapeutics a Smart Buy on the Dip?
09:47am, Monday, 27'th Mar 2023 The Motley Fool
The stock recently fell around 25% for reasons that had nothing to do with its lead program.
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval
05:51pm, Thursday, 23'rd Mar 2023 Zacks Investment Research
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data
03:18pm, Wednesday, 22'nd Mar 2023 Zacks Investment Research
Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate
Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2023
03:00pm, Wednesday, 22'nd Mar 2023 Benzinga
Upgrades
Clarkson Capital Markets upgraded the previous rating for Transocean Ltd (NYSE:RIG) from Neutral to Buy. In the fourth quarter, Transocean showed an EPS of $0.49, compared to $0.19 from the y
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data
01:00pm, Wednesday, 22'nd Mar 2023
Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
09:55am, Wednesday, 22'nd Mar 2023 The Motley Fool
It's not the end of the story for this once high-flying biotech stock.
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
05:55am, Wednesday, 22'nd Mar 2023
Analysts had lofty expectations for Altimmune and the prospects for pemvidutide in treating obesity. However, pemvidutide's side effects in a phase 2 study were concerning.
